AUVELITY is a novel, oral, NMDA receptor antagonist with multimodal activity approved for the treatment of MDD in adults. AUVELITY is a proprietary extended-release oral tablet containing ...

Produced by SELF with AUVELITY (dextromethorphan HBr and bupropion HCl; 45 / 105 mg) | Fitness coach and mental health advocate Kendall Toole opens up about living with depression. Through therapy, ...

Axsome Therapeutics AXSM has been witnessing a strong sales uptake for its lead marketed drug, Auvelity (AXS-05), which is approved for treating major depressive disorder. Since its launch in the ...

Recon: FDA approves Axsome’s depression drug Auvelity after year-long wait; Gilead scores first global approval for HIV treatment Welcome to Regulatory Reconnaissance, your daily regulatory news and ...

Net loss (GAAP) narrowed to $48.0 million, with EPS (GAAP) at $(0.97), beating GAAP estimates by $0.08 per share. AUVELITY (major depressive disorder) and SUNOSI (excessive daytime sleepiness) both ...